Looking for endoscopic features of cytomegalovirus colitis: A study of 187 patients with active ulcerative colitis, positive and negative for cytomegalovirus

Inflammatory Bowel Diseases

Volumn 19, Issue 6, 2013, Pages 1156-1163

  Iida, Takayuki ^a   Ikeya, Kentaro ^a   Watanabe, Fumitoshi ^a   Abe, Jinro ^a   Maruyama, Yasuhiko ^b   Ohata, Akihiko ^b   Teruyuki, Shimura ^b   Sugimoto, Ken ^c   Hanai, Hiroyuki ^a  

^a Hamamatsu South Hospital   (Japan)

^b FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antigenemia; Colonoscopy; Cytomegalovirus; Cytomegalovirus reactivation; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MERCAPTOPURINE; VIRUS DNA;

ADULT; ARTICLE; BLOOD SAMPLING; CIRCULAR ULCER; COLON ULCER; COLONOSCOPY; CYTAPHERESIS; CYTOMEGALOVIRUS COLITIS; CYTOMEGALOVIRUS INFECTION; DEEP ULCER; DISEASE EXACERBATION; ENDOSCOPY; FEMALE; HUMAN; INFECTION RATE; LONGITUDINAL ULCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PUNCHED OUT ULCER; REAL TIME POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; VIRUS REACTIVATION;

ADULT; COLITIS, ULCERATIVE; COLONOSCOPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84879239052     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828075ce     Document Type: Article

References (48)

1. Hommes DW, Sterringa G, van Deventer SJ, et al. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004;10:245-250.
2. Surawicz CM, Myerson D. Self-limited cytomegalovirus colitis in immunocompetent individuals. Gastroenterology. 1988;94:194-199.
3. Grundy JE. Virologic and pathogenetic aspects of cytomegalovirus infection. Rev Infect Dis. 1990;12(suppl 7):S711-S719.
4. Cheung AN, Ng I. Cytomegalovirus infection of the gastrointestinal tract in non-AIDS patients. Am J Gastroenterol. 1993;88:1882-1886.
5. Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993;119:924-935.
6. Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr. 1991;4(suppl 1):S29-S35.
7. Kaplan B, Meier-Kriesche HU, Jacobs MG, et al. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis. 1999;34:65-68.
8. Diepersloot RJ, Kroes AC, Visser W, et al. Acute ulcerative proctocolitis associated with primary cytomegalovirus infection. Arch Intern Med. 1990;150:1749-1751.
9. Loftus EV Jr, Alexander GL, Carpenter HA. Cytomegalovirus as an exacerbating factor in ulcerative colitis. J Clin Gastroenterol. 1994;19:306-309.
10. Lortholary O, Perronne C, Leport J, et al. Primary cytomegalovirus infection associated with the onset of ulcerative colitis. Eur J Clin Microbiol Infect Dis. 1993;12:570-572.
11. Orvar K, Murray J, Carmen G, et al. Cytomegalovirus infection associated with onset of inflammatory bowel disease. Dig Dis Sci. 1993;38: 2307-2310.
12. Kaneko T, Matsuda R, Taguri M, et al. Clostridium difficile infection in patients with ulcerative colitis: investigations of risk factors and efficacy of antibiotics for steroid refractory patients. Clin Res Hepatol Gastroenterol. 2011;35:315-320.
13. Truelove SC, Witts LJ. Cortisone in the treatment of ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955;2:1041-1048.
14. Rachmilewitz D (on behalf of An International Study Group). Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ. 1989;298:82-86.
15. Hanai H, Watanabe F, Takeuchi K, et al. Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol. 2003;1:28-35.
16. Matsuoka K, Iwao Y, Mori T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 2007;102:331-337.
17. Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy against cytomegalovirus (CMV) disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25: 765-769.
18. Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single centre experience in Japan. Bone Marrow Transplant. 2001;27:437-444.
19. Mori T, Okamoto S, Watanabe R, et al. Dose-adjusted pre-emptive therapy for cytomegalovirus disease based on real time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:777-782.
20. Tanaka N, Kimura H, Iida K, et al. Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J Med Virol. 2000;60:455-462.
21. Rahier JF, Ben-Horin S, Chowers Y, et al; on behalf of the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3: 47-91.
22. Yoshino T, Nakase H, Ueno S, et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis. 2007;13:1516-1521.
23. Powell RD, Werner NE, Levine RS, et al. Cytomegalic inclusion disease and ulcerative colitis: report of a case in a young adult. Am J Med. 1961; 30:334-340.
24. Pfau P, Kochman ML, Furth EE, et al. Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient. Am J Gastroenterol. 2001;96:895-899.
25. Osaki R, Andoh A, Tsujikawa T, et al. Acute cytomegalovirus infection superimposed on corticosteroid naïve ulcerative colitis. Inter Med. 2008; 47:1341-1344.
26. Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46(suppl 10):S59-S65.
27. Kaufman HS, Kahn AC, Iacobuzio-Donahue C, et al. Cytomegaloviral enterocolitis: clinical associations and outcome. Dis Colon Rectum. 1999; 42:24-30.
28. Nankervis GA, Kumar ML. Diseases produced by cytomegalovirus. Med Clin North Am. 1978;62:1021-1035.
29. Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001-2008.
30. Berk T, Gordon SJ, Choi HY, et al. Cytomegalovirus infection of the colon: a possible role in exacerbation of inflammatory bowel disease. Am J Gastroenterol. 1985;80:355-360.
31. Begos DG, Rappaport R, Jain D. Cytomegalovirus infection masquerading as an ulcerative colitis flare-up: case report and review of the literature. Yale J Biol Med. 1996;69:323-328.
32. Vega R, Bertran X, Menacho M, et al. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94: 1053-1056.
33. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16:1620-1627.
34. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101:2857-2865.
35. Kishore J, Ghoshal U, Ghoshal UC. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155-1160.
36. Papadakis KA, Tung JK, Binder SW. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:2137-2142.
37. Maconi G, Colombo E, Zerbi P, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis. 2005;37:418-423.
38. Ginsburg CH, Dambrauskas JT, Ault KA. Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect. Gastroenterology. 1983;85:846-851.
39. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001;47:1297-1301.
40. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis. 2004;17:357-361.
41. Nakase H, Tsutomu Chiba T. TNF-α is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience. Inflamm Bowel Dis. 2010;16:550-551.
42. Saniabadi AR, Hanai H, Fukunaga K, et al. Therapeutic leucocytapheresis for inflammatory bowel disease. Transf Apher Sci. 2007;37:191-200.
43. Hanai H, Takeda Y, Saniabadi AR, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58.
44. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today. 1995;16:21-26.
45. Nikolaus S, Bauditz J, Gionchetti P. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut. 1998;42:470-476.
46. Rowshani AT, Bemelman FJ, van Leeuwen EM, et al. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation. 2005;79:381-386.
47. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A. 1998;95:3937-3942.
48. Smith PD, Saini SS, Raffeld M, et al. Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest. 1992;90:1642-1648.